Compare CGBD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGBD | CGEM |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.2M | 904.7M |
| IPO Year | N/A | 2020 |
| Metric | CGBD | CGEM |
|---|---|---|
| Price | $10.69 | $13.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $12.92 | ★ $30.13 |
| AVG Volume (30 Days) | 570.6K | ★ 881.8K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.80 | $5.20 |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.64 | $5.68 |
| 52 Week High | $14.32 | $16.74 |
| Indicator | CGBD | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 42.75 |
| Support Level | $10.68 | $12.41 |
| Resistance Level | $12.17 | $16.21 |
| Average True Range (ATR) | 0.30 | 0.94 |
| MACD | -0.10 | -0.16 |
| Stochastic Oscillator | 3.80 | 11.57 |
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.